Abstract
Introduction
The aim of safety pharmacology is to detect potential undesirable pharmacodynamic effects of new chemical entities during drug development process. Cardiotoxicity is one of the main side effects of most new chemical entities. Unfortunately, the cardiotoxic side effects of many new chemical entities are only detected during phase I and phase II clinical trials, whereas in-vitro and preclinical studies did not detect any malignant effect.
Limitations of in-vitro and preclinical trials are in part due to the lack of variability of those research models. Humans present important inter-subject variabilities in both their anatomical (i.e. size) and electrophysiological properties. Populations of mathematical models have appeared as a useful tool to evaluate drug safety in-silico accounting for the variability between patients [1] . However, standard mathematical models at tissue level require time-consuming simulations and complex inducibility protocols to confirm or discard re-entries and arrhythmia maintenance.
In this paper we present a novel method to evaluate safety pharmacology in-silico. This novel method allows to estimate the pro-arrhythmic or anti-arrhythmic effect of a drug on each individual member of population of models without the need of performing time-consuming simulations.
Specifically, a proof of concept study is presented evaluating the effect of isoproterenol (a non-selective β adrenoreceptor agonist) on atrial fibrillation (AF) inducibility in a multivariable scenario, including a population of mathematical models with both variability on ion conductances and on tissue size. This novel approach will be validated by comparing the prediction of the novel methodology with the results of 2D mathematical model simulations.
2.
Materials and Methods
Population of models
An experimentally population of 127 human AF tissue mathematical models [2] reproducing the variability observed in 149 chronic AF patients was used [1] . As described before [2] , a atrial cardiomyocytes electrophysiological model was used as basis for the generation of a population of models in which gNa, INak, gK1, gCaL, gKur , IKCa, Ko, Na0 and the diffusion was varied.
Substrate size is an anatomical feature that determines the maintenance of AF [3] . For this purpose, two different square planes, with 100µm inter-nodal distance, corresponding to normal (400 X 400 nodes, 15 cm 2 ) and a dilated (450 x 450 nodes, 20 cm 2 ) atria were tested in order to evaluate the dependence on tissue size on arrhythmogeneity.
Safety pharmacology
To simulate the effect of a drug, a simple pore model was implemented in the model:
Where G0 is the initial conductance of the channel, Di is the concentration of the drug and IC50 is the concentration of the drug that reduces by 50% the channel current. For this experiment, the simulated drug was isoproterenol. Isoproterenol is a a non-selective β adrenoreceptor agonist used for the treatment of bradycardia (slow heart rate) but that can present pro-arrhythmic effects and AF inducibility in some patients [4] . Specifically, INa, IKr and ICaL were modified and the concentration for the drug was set to 5•10 -3 mM [5] .
Workflow of the model
For each of the 127 mathematical models and tissue sizes, reentrant activity was induced with the S1S2 protocol. Optimal S2 triggering was computed for each model based on its specific properties and on the sodium channel availability. Furthermore, a minimum voltage for triggering was also added as a boundary condition. The threshold established for both sodium channel availability and voltage were 4·10 -5 u.a. and -75mV respectively. Following an S1S2 protocol, simulation continued for 5 seconds. At that point, if the reentrant activity continued, the drug was applied to evaluate its antiarrhythmic effect and the simulation was continued for 5 more seconds. In case the reentrant activity did not continue, the drug was applied to the model and S1S2 protocol was applied again to evaluate the potential proarrhythmic effect of the drug.
For each of the four scenarios (i.e. (A) basal 15cm 2 , (B) drug 15cm 2 , (C) basal 20cm 2 , (D) drug 20cm 2 ) the duration of the reentrant activity after the induction protocol was quantified. Effects of the drug on AF inducibility were defined as the maintenance difference (MD), or the difference in time between AF duration with and without drug infusion (groups A vs. B and C vs. D) or for different atrial sizes (A vs. C).
Then, after computing the effect of the drug or the dependence with size, each simulation was classified as: (1) antiarrhythmic if MD was decreased, (2) proarrhythmic if MD was increased or (3) no effect if MD remained unchanged.
All simulations were performed in a GPU nVIDIA TESLA C2057 system [1] .
Canonical Correlation Analysis
The goal of the novel methodology was to predict the proarrhythmic, antiarrhythmic or neutral effect of the drug on each mathematical model without the need of performing the long simulations described in section 2.3. Specifically, a regression model dependent on conductances and tissue size was developed. The regression model was estimated by using Canonical Correlation Analysis (CCA), a dimension reduction method that maximizes the correlations between two multidimensional variables in a compact subspace.
CCA was independently trained for over 80% randomly selected models of the two population of models (i.e. 101 models in a basal atrium and 101 models in the dilated atria) to confirm the robustness of the methodology. CCA transformation matrices were used as a regression method to estimate the predictability of the method over the test set (i.e. 26 mathematical models for each of the two sizes).
Results

Effect of size on arrhythmogenicity
In Figure 1 the inducibility protocol for 1 of the 127 models is depicted, both for basal tissue (i.e. 15cm
2 ) and for dilated tissue (i.e. 20cm
2 ). Notice that for both atrial sizes, the S2 interval captured and induced reentries. Nevertheless, in the smaller atria the arrhythmia selfterminate after 3 reentries, whereas for the larger atria the reentry was able to stabilize the arrhythmia during the entire simulation. Results for the entire database are shown in Table 1 . As expected, larger atrium sizes allowed the maintenance of more reentries, and consequently the stabilization of AF in a larger number of models Figure 2 . Example of proarrhythmic and antiarrhythmic effect of isoproterenol for two different models. Figure 2 illustrates opposed effects of the same drug concentration in two different models of the population for a size of 15cm 2 . A proarrhythmic effect of isoproterenol can be observed in the left panel: whereas during basal conditions, the S2 pacing produced a reentry that selfterminated after a couple of reentries, after the administration of the isoproterenol, the S2 pacing produced a stable arrhythmia. Interestingly, in the example on the right isoproterenol produced an antiarrhythmic effect: during basal conditions, the S2 interval induced up to 4 reentries (i.e. 542 ms of reentry) but after the administration of the isoproterenol, the S2 pacing was only able to induce just one reentry (i.e. 111 ms of reentry).
Effect of drug on arrhythmogenicity
Results for the entire database and both atrial sizes are depicted in Table 2 . Interestingly, for basal size isoproterenol was proarrhythmic in 63 models (49.32%), antiarrhythmic in 56 models (43.83%) and had no effect in the remaining 8 (6.85%).
For dilated size atria, isoproterenol was proarrhythmic in 81 models (63.77%), antiarrhythmic in 42 models (33.34%) and had no effect in the remaining 4 (2.89%). As observed, the same drug could be proarrhythmic or antiarrhythmic depending on the atrial size, highlighting that safety pharmacology should not be restricted to single cell simulations, but also at whole tissue level.
Canonical Correlation Analysis (CCA)
The analysis shown in sections 3.1 and section 3.2 required 525 hours of simulation in a nVIDIA TESLA C2057 GPU system. Extrapolation of those results to other atrial sizes, higher population of models of more drugs may become dramatically time consuming and unachievable for reasonable simulation periods.
Distribution of the 101 training sets of mathematical models over the CCA transformation are depicted in figure  3 . As it can be observed, for both atrial sizes, the first component of the CCA model was able to differentiate between those models in which the isoproterenol was proarrhythmic (i.e. blue dots) and those in which the isoproterenol was antiarrhythmic (i.e. red dots). The second component (left panel) could serve to identify those models in which the drug had no effect (i.e. yellow dots).
Notice how the pattern of distribution of CCA components was similar for both atrial sizes confirming the robustness of the procedure.
When the trained regression model was used to estimate the effect of the drug on simulations not used for the training (20%), a prediction with an accuracy of 96% for basal atria and 100% for dilated atria.
In addition to the predictability, CCA model allowed the identification of most relevant conductivities for the construction of the regression model. Specifically, for the basal atria of 15cm2, the most influencing parameters were gCaL, and Nao, whereas for the dilated atria of 20cm2, the most influencing parameters were gNa, gNak and gK1. 
Discussion and conclusion
A platform for the testing the pro and antiarrhytmicity of drugs in silico has been developed and evaluated on a set of 127 individuals in a multivariable scenario. The effect of drug on a population of models was studied for the case of isoproterenol in two different tissue sizes, accounting for either a healthy and dilated atria. This platform enables to evaluation of safety pharmacology considering realistic inter-subject variability.
In addition, a regression model based on CCA has demonstrated to be a robust procedure to predict the arrhythmogenicity of a drug without needing long and complex simulations. Furthermore, this methodology allowed the identification of most relevant parameters to predict drug effect.
Present results should be corroborated with a larger number of drugs and atrial tissue sizes, nevertheless, this approach provides a new opportunity to improve safety pharmacology tests and increase the efficacy of new drug developments, setting the base for personalized medicine.
